ANL Stock Overview
A clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Adlai Nortye Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.61 |
| 52 Week High | US$19.30 |
| 52 Week Low | US$3.21 |
| Beta | 0 |
| 11 Month Change | -71.69% |
| 3 Month Change | -60.02% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -75.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| ANL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.8% | -2.2% | 0.7% |
| 1Y | n/a | 6.7% | 23.3% |
Return vs Industry: Insufficient data to determine how ANL performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how ANL performed against the US Market.
Price Volatility
| ANL volatility | |
|---|---|
| ANL Average Weekly Movement | 22.6% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ANL's share price has been volatile over the past 3 months.
Volatility Over Time: ANL's weekly volatility has increased from 16% to 23% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 127 | Carsten Lu | www.adlainortye.com |
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1.
Adlai Nortye Ltd. Fundamentals Summary
| ANL fundamental statistics | |
|---|---|
| Market cap | US$124.35m |
| Earnings (TTM) | -US$104.87m |
| Revenue (TTM) | US$5.00m |
26.6x
P/S Ratio-1.3x
P/E RatioIs ANL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANL income statement (TTM) | |
|---|---|
| Revenue | US$5.00m |
| Cost of Revenue | US$0 |
| Gross Profit | US$5.00m |
| Other Expenses | US$109.87m |
| Earnings | -US$104.87m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.84 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,097.42% |
| Debt/Equity Ratio | 38.2% |
How did ANL perform over the long term?
See historical performance and comparison